Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 12/20 | 0.58 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.58 |
| ▸ | HTR3B | O95264 | 4/20 | 0.58 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.58 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.58 |
| ▸ | CNR1 | P21554 | 3/20 | 0.54 |
| ▸ | CNR2 | P34972 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22416267 | 1.00 | HTR3A (0.58) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL9027739 | 1.00 | HTR3A (0.58) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL16378030 | 0.96 | CNR1 (0.57) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL22416052 | 0.96 | CNR1 (0.57) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL9028063 | 0.90 | HTR3A (0.61) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL9027144 | 0.89 | HTR3A (0.66) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL9027450 | 0.87 | HTR3A (0.67) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL9028508 | 0.87 | CNR2 (0.73) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL9027784 | 0.87 | HTR3A (0.59) | HTR3AHTR3EHTR3BHTR3DHTR3C | |
| SCHEMBL9027809 | 0.86 | HTR3A (0.60) | HTR3AHTR3EHTR3BHTR3DHTR3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403802-B2 | Heterocyclic compound and use therefor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-08-02 | — | — | US | disclosed |
| US-20150126487-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126487-A1 | HETEROCYCLIC COMPOUND AND USE THEREFOR | CHRM1, CHRM4, CHRM2 | HTR3A 163/4885HTR3E 304/4885HTR3B 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.